148 related articles for article (PubMed ID: 11830482)
21. [Chromosome study on chronic lymphocytic leukemia using CpG-oligodeoxynucleotide as immunostimulant agent].
Wu Y; Xue Y; Chen S; Yao L; Jiang H; Zhang J; Shen J; Pan J; Wang Y; Bai S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):86-91. PubMed ID: 20140876
[TBL] [Abstract][Full Text] [Related]
22. Immunotoxin-mediated inhibition of chronic lymphocytic leukemia cell proliferation in humans.
Siena S; Bregni M; Formosa A; Brando B; Marenco P; Lappi DA; Bonadonna G; Gianni AM
Cancer Res; 1989 Jun; 49(12):3328-32. PubMed ID: 2785850
[TBL] [Abstract][Full Text] [Related]
23. Immunostimulation by cytosine-phosphate-guanine oligodeoxynucleotides in combination with IL-2 can improve the success rate of karyotype analysis in chronic lymphocytic leukaemia.
Lin X; Chen J; Huang H
Br J Biomed Sci; 2016 Jul; 73(3):110-114. PubMed ID: 27327088
[TBL] [Abstract][Full Text] [Related]
24. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
Powell DJ; Felipe-Silva A; Merino MJ; Ahmadzadeh M; Allen T; Levy C; White DE; Mavroukakis S; Kreitman RJ; Rosenberg SA; Pastan I
J Immunol; 2007 Oct; 179(7):4919-28. PubMed ID: 17878392
[TBL] [Abstract][Full Text] [Related]
25. Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine.
Wolska A; Cebula-Obrzut B; Smolewski P; Robak T
Leuk Lymphoma; 2013 Jun; 54(6):1268-78. PubMed ID: 23078646
[TBL] [Abstract][Full Text] [Related]
26. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
Jahrsdorfer B; Mühlenhoff L; Blackwell SE; Wagner M; Poeck H; Hartmann E; Jox R; Giese T; Emmerich B; Endres S; Weiner GJ; Hartmann G
Clin Cancer Res; 2005 Feb; 11(4):1490-9. PubMed ID: 15746051
[TBL] [Abstract][Full Text] [Related]
27. The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs.
Bjersing JL; Eriksson K; Tarkowski A; Collins LV
Inflammation; 2004 Feb; 28(1):39-51. PubMed ID: 15072229
[TBL] [Abstract][Full Text] [Related]
28. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation.
Jahrsdörfer B; Blackwell SE; Wooldridge JE; Huang J; Andreski MW; Jacobus LS; Taylor CM; Weiner GJ
Blood; 2006 Oct; 108(8):2712-9. PubMed ID: 16809616
[TBL] [Abstract][Full Text] [Related]
29. Immunostimulatory CpG-oligodeoxynucleotides induce a factor that inhibits macrophage adhesion.
Macfarlane DE; Manzel L
J Lab Clin Med; 1999 Nov; 134(5):501-9. PubMed ID: 10560944
[TBL] [Abstract][Full Text] [Related]
30. New perspectives on the approach to chronic lymphocytic leukemia.
Goodman MG; Spinosa JC; Saven A; Piro LD; Wormsley S
Leuk Lymphoma; 1996 Jun; 22(1-2):1-10. PubMed ID: 8724523
[TBL] [Abstract][Full Text] [Related]
31. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells.
Moseman EA; Liang X; Dawson AJ; Panoskaltsis-Mortari A; Krieg AM; Liu YJ; Blazar BR; Chen W
J Immunol; 2004 Oct; 173(7):4433-42. PubMed ID: 15383574
[TBL] [Abstract][Full Text] [Related]
32. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.
Attia P; Powell DJ; Maker AV; Kreitman RJ; Pastan I; Rosenberg SA
J Immunother; 2006; 29(2):208-14. PubMed ID: 16531821
[TBL] [Abstract][Full Text] [Related]
33. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
Mankaï A; Buhé V; Hammadi M; Youinou P; Ghedira I; Berthou C; Bordron A
Ann N Y Acad Sci; 2009 Sep; 1173():721-8. PubMed ID: 19758221
[TBL] [Abstract][Full Text] [Related]
34. CLL immunotoxins.
Frankel AE; Kreitman RJ
Leuk Res; 2005 Sep; 29(9):985-6. PubMed ID: 16038723
[TBL] [Abstract][Full Text] [Related]
35. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM
J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783
[TBL] [Abstract][Full Text] [Related]
36. Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells.
Wu CC; Castro JE; Motta M; Cottam HB; Kyburz D; Kipps TJ; Corr M; Carson DA
Hum Gene Ther; 2003 Jun; 14(9):849-60. PubMed ID: 12828856
[TBL] [Abstract][Full Text] [Related]
37. Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference.
Castro JE; Prada CE; Aguillon RA; Kitada S; Fukuda T; Motta M; Wu C; Dicker F; Sun G; Wang JY; Carson DA; Reed JC; Kipps TJ
Leukemia; 2006 Apr; 20(4):680-8. PubMed ID: 16498393
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.
Gupta R; Yan XJ; Barrientos J; Kolitz JE; Allen SL; Rai K; Chiorazzi N; Mongini PKA
J Immunol; 2018 Sep; 201(5):1570-1585. PubMed ID: 30068596
[TBL] [Abstract][Full Text] [Related]
39. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
Biberacher V; Decker T; Oelsner M; Wagner M; Bogner C; Schmidt B; Kreitman RJ; Peschel C; Pastan I; Meyer Zum Büschenfelde C; Ringshausen I
Haematologica; 2012 May; 97(5):771-9. PubMed ID: 22180432
[TBL] [Abstract][Full Text] [Related]
40. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
